抗血小板药物和本地动脉静脉的功能障碍
Ioanna Pouliopoulou1, Stefanos Roumeliotis1, Konstantinos Leivaditis1
12nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
VASA. Zeitschrift fur Gefasskrankheiten
|August 21, 2025
概括
抗血小板治疗,特别是提克洛皮丁和克洛皮多格勒,可以改善动脉静脉 (AVF) 的通透性,并减少功能障碍. 这一系统审查证实了这些药物的安全性和有效性,以维持透析接入的AVF功能.
科学领域:
- 肝脏病学
- 血管外科
- 药理学
背景情况:
- 原生动脉静脉 (AVF) 功能障碍是一个显著的并发症.
- 预防AVF功能障碍对于有效的血液透析至关重要.
- 抗血小板治疗是保持AVF通透性的潜在策略.
研究的目的:
- 系统地审查抗血小板治疗在预防本源性AVF功能障碍方面的安全性和有效性.
- 评估抗血小板药物对初级AVF通透率和二次结果的影响.
主要方法:
- 遵循PRISMA 2020指南的随机对照试验 (RCT) 的系统审查和元分析.
- 包括评估抗血小板治疗后AVF形成的RCT.
- 主要终点:AVF的初级通透性;次要终点:成熟,放弃,出血.
主要成果:
- 分析了12个RCT (2491名患者) 的抗血小板药物,包括阿司匹林,克洛皮德林,蒂克洛皮丁和二皮里达摩尔.
- 术后使用抗血小板药物改善了AVF的初级通透性 (OR 2. 28).
- 每日两次250毫克的提克洛皮丁显著改善了透视度 (OR 3. 48);其他药物有不同的作用. 在成熟,放弃或出血方面没有发现显著差异.
结论:
- 抗血小板治疗是安全的,有效地保持本源的AVF通透性.
- 蒂克洛皮丁和克洛皮多格勒似乎是改善AVF通透性的关键因素.
- 腺二酸盐 (ADP) 受体对抗剂在维持AVF通透性方面表现有前途.
相关概念视频
Hemodialysis I: Introduction
287
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
287
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K


